A PHASE-II TRIAL OF 5-FLUOROURACIL, FOLINIC ACID, VINORELBINE IN PRETREATED PATIENTS WITH METASTIC COLORECTAL-CANCER
| العنوان: | A PHASE-II TRIAL OF 5-FLUOROURACIL, FOLINIC ACID, VINORELBINE IN PRETREATED PATIENTS WITH METASTIC COLORECTAL-CANCER |
|---|---|
| المؤلفون: | A. Tortoriello, Luigi Bucci, L Fei, Michele Santangelo, N Dimartino, G. Scaramellino, G. Gesue, G Desena, G. Facchini, Rv Iaffaioli, A. Finizio, B Antonelli, Francesco Caponigro |
| المصدر: | ResearcherID Europe PubMed Central |
| بيانات النشر: | Spandidos Publications, 1995. |
| سنة النشر: | 1995 |
| مصطلحات موضوعية: | Oncology, Cancer Research, Chemotherapy, medicine.medical_specialty, Colorectal cancer, business.industry, medicine.drug_class, medicine.medical_treatment, Cancer, General Medicine, medicine.disease, Vinorelbine, Vinca alkaloid, Folinic acid, Regimen, Fluorouracil, Internal medicine, medicine, business, medicine.drug |
| الوصف: | 43 patients with metastatic colorectal cancer pretreated with 5-fluorouracil-based chemotherapy received vinorelbine plus 5-fluorouracil plus folinic acid with the aim of evaluating vinorelbine activity in advanced colorectal cancer and its potential synergism with commonly used drugs. 9 partial responses were observed, for an overall objective response rate of 20.9%. 20 additional patients had stable disease (46.5%). Median duration of response was 7 months. Median survival from the start of treatment was 6 months. The main toxic effect was myelosuppression. We conclude that our regimen is active enough to warrant further evaluation in advanced colorectal cancer. Introduction The results of systemic chemotherapy in metastatic colorectal cancer are quite discouraging. In fact, 5-fluorouracil (5-FU)+ folinic acid (FA), which is presently recognized as the treatment of choice, results in only 23-31% response rates with a median survival of approximately 12 months in untreated patients (1,2). Vinorelbine (VLB) is a new semi-synthetic vinca alkaloid (3) which has shown objective responses between 26% and 44% in untreated non-small cell lung cancer (Yokoyama |
| تدمد: | 1791-2431 1021-335X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c73cde72751c5a7f00f32ec8ebe31c53 https://doi.org/10.3892/or.2.4.513 |
| رقم الأكسشن: | edsair.doi.dedup.....c73cde72751c5a7f00f32ec8ebe31c53 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17912431 1021335X |
|---|